A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects With Indolent Systemic Mastocytosis
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Sarilumab (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2019 Planned End Date changed from 1 Jul 2027 to 1 Aug 2024.
- 20 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 3 Jun 2019 to 26 Jun 2019.
- 24 May 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 May 2019 3 June 2019